Metagenomi Therapeutics, Inc. (MGX)
Nasdaq: MGX · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2019
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Report filed | Mar 5, 2026 | Mar 17, 2025 | Mar 27, 2024 |
| Revenue | 25,210 | 52,295 | 44,756 |
| Research and development | 94,433 | 109,179 | 94,403 |
| General and administrative | 26,790 | 32,017 | 28,845 |
| Total operating expenses | 121,223 | 141,196 | 123,248 |
| Operating income | -96,013 | -88,901 | -78,492 |
| Interest and investment income | 9,470 | 14,722 | 15,468 |
| Other income (expense), net | -91 | -207 | -74 |
| Total non-operating income (expense) | 8,087 | 5,330 | 18,264 |
| Income before income taxes | -87,926 | -83,571 | -60,228 |
| Income tax expense | -58 | -5,513 | 8,027 |
| Net income including non-controlling interests | -87,868 | -78,058 | -68,255 |
| Net income | -87,868 | -78,058 | -68,255 |
| Net income to common shareholders | -87,868 | -78,058 | -68,255 |
| Earnings per share, basic | -2.36 | -2.36 | -20.05 |
| Earnings per share, diluted | -2.36 | -2.36 | -20.05 |
| Weighted average shares, basic | 37,251,050 | 33,027,889 | 3,404,585 |
| Weighted average shares, diluted | 37,251,050 | 33,027,889 | 3,404,585 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestOther income (expense), net gains and costs outside the business
us-gaap:OtherNonoperatingIncomeExpenseTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income including non-controlling interests the whole group's profit, minority holders' share included
us-gaap:ProfitLossNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossNet income to common shareholders what is left for common shareholders
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasicEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding